Advances in therapy for spinal muscular atrophy: promises and challenges

[1]  M. Schroth,et al.  Clinical trial of L‐Carnitine and valproic acid in spinal muscular atrophy type I , 2018, Muscle & nerve.

[2]  A. T. van der Ploeg,et al.  The Dilemma of Two Innovative Therapies for Spinal Muscular Atrophy. , 2017, The New England journal of medicine.

[3]  Brian K. Kaspar,et al.  Single‐Dose Gene‐Replacement Therapy for Spinal Muscular Atrophy , 2017, The New England journal of medicine.

[4]  R. J. Ramamurthi,et al.  Nusinersen versus Sham Control in Infantile‐Onset Spinal Muscular Atrophy , 2017, The New England journal of medicine.

[5]  S. Ackerman,et al.  Regulation of mRNA Translation in Neurons—A Matter of Life and Death , 2017, Neuron.

[6]  Ewout J. N. Groen,et al.  In Vivo Translatome Profiling in Spinal Muscular Atrophy Reveals a Role for SMN Protein in Ribosome Biology , 2017, Cell reports.

[7]  R. Finkel,et al.  Spinal muscular atrophy: A changing phenotype beyond the clinical trials , 2017, Neuromuscular Disorders.

[8]  Hanns Lochmüller,et al.  Prevalence, incidence and carrier frequency of 5q–linked spinal muscular atrophy – a literature review , 2017, Orphanet Journal of Rare Diseases.

[9]  E. Mercuri,et al.  Safety and efficacy of olesoxime in patients with type 2 or non-ambulatory type 3 spinal muscular atrophy: a randomised, double-blind, placebo-controlled phase 2 trial , 2017, The Lancet Neurology.

[10]  B. Wirth,et al.  Advances in understanding the role of disease-associated proteins in spinal muscular atrophy , 2017, Expert review of proteomics.

[11]  T. Friedmann.  Gene therapy for spinomuscular atrophy: a biomedical advance, a missed opportunity for more equitable drug pricing , 2017, Gene Therapy.

[12]  K. Talbot,et al.  The SMA Trust: the role of a disease-focused research charity in developing treatments for SMA , 2017, Gene Therapy.

[13]  E. Androphy,et al.  How the discovery of ISS-N1 led to the first medical therapy for spinal muscular atrophy , 2017, Gene Therapy.

[14]  N. King,et al.  New treatments for serious conditions: ethical implications , 2017, Gene Therapy.

[15]  G. Mentis,et al.  Reduced sensory synaptic excitation impairs motor neuron function via Kv2.1 in spinal muscular atrophy , 2017, Nature Neuroscience.

[16]  L. H. van den Berg,et al.  Cardiac pathology in spinal muscular atrophy: a systematic review , 2017, Orphanet Journal of Rare Diseases.

[17]  J. Henne,et al.  A qualitative study of perceptions of meaningful change in spinal muscular atrophy , 2017, BMC Neurology.

[18]  Rachael A. Powis,et al.  Bioenergetic status modulates motor neuron vulnerability and pathogenesis in a zebrafish model of spinal muscular atrophy , 2017, PLoS genetics.

[19]  A. Aartsma-Rus.  FDA Approval of Nusinersen for Spinal Muscular Atrophy Makes 2016 the Year of Splice Modulating Oligonucleotides. , 2017, Nucleic acid therapeutics.

[20]  C. Lorson,et al.  Plastin-3 extends survival and reduces severity in mouse models of spinal muscular atrophy. , 2017, JCI insight.

[21]  E. Ottesen,et al.  Diverse role of survival motor neuron protein. , 2017, Biochimica et biophysica acta. Gene regulatory mechanisms.

[22]  R. Finkel,et al.  Content validity and clinical meaningfulness of the HFMSE in spinal muscular atrophy , 2017, BMC Neurology.

[23]  Francesco Muntoni,et al.  Revised Hammersmith Scale for spinal muscular atrophy: A SMA specific clinical outcome assessment tool , 2017, PloS one.

[24]  K. Swoboda,et al.  Emerging therapies and challenges in spinal muscular atrophy , 2017, Annals of neurology.

[25]  W. Rossoll,et al.  The Survival of Motor Neuron Protein Acts as a Molecular Chaperone for mRNP Assembly. , 2017, Cell reports.

[26]  Maureen M Lynes,et al.  Supplemental Information Single-Cell Analysis of SMN Reveals Its Broader Role in Neuromuscular Disease , 2017 .

[27]  A. Hoischen,et al.  Neurocalcin Delta Suppression Protects against Spinal Muscular Atrophy in Humans and across Species by Restoring Impaired Endocytosis. , 2017, American journal of human genetics.

[28]  Rachael A. Powis,et al.  Survival of motor neurone protein is required for normal postnatal development of the spleen , 2017, Journal of anatomy.

[29]  L. H. van den Berg,et al.  Association of motor milestones, SMN2 copy and outcome in spinal muscular atrophy types 0–4 , 2017, Journal of Neurology, Neurosurgery & Psychiatry.

[30]  R. Kothary,et al.  Immune dysregulation may contribute to disease pathogenesis in spinal muscular atrophy mice , 2017, Human molecular genetics.

[31]  M. Toumi,et al.  A comparative study of orphan drug prices in Europe , 2017, Journal of market access & health policy.

[32]  R. Finkel,et al.  Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study , 2016, The Lancet.

[33]  T. Gillingwater.  Dawn of a new therapeutic era for spinal muscular atrophy , 2016, The Lancet.

[34]  P. Neumann,et al.  Willingness to Pay for a Newborn Screening Test for Spinal Muscular Atrophy. , 2017, Pediatric neurology.

[35]  L. H. van den Berg,et al.  A Comparative Study of SMN Protein and mRNA in Blood and Fibroblasts in Patients with Spinal Muscular Atrophy and Healthy Controls , 2016, PloS one.

[36]  M. Ferrer,et al.  ML372 blocks SMN ubiquitination and improves spinal muscular atrophy pathology in mice. , 2016, JCI insight.

[37]  Gillian K. Maxwell,et al.  Survival Motor Neuron (SMN) protein is required for normal mouse liver development , 2016, Scientific Reports.

[38]  M. Bowerman,et al.  Systemic peptide-mediated oligonucleotide therapy improves long-term survival in spinal muscular atrophy , 2016, Proceedings of the National Academy of Sciences.

[39]  A. Büschges,et al.  The Power of Human Protective Modifiers: PLS3 and CORO1C Unravel Impaired Endocytosis in Spinal Muscular Atrophy and Rescue SMA Phenotype. , 2016, American journal of human genetics.

[40]  J. Stubbings,et al.  Evaluation of Specialty Drug Price Trends Using Data from Retrospective Pharmacy Sales Transactions. , 2016, Journal of managed care & specialty pharmacy.

[41]  Nimrod Miller,et al.  Motor neuron mitochondrial dysfunction in spinal muscular atrophy. , 2016, Human molecular genetics.

[42]  M. Horne,et al.  Enhancing survival motor neuron expression extends lifespan and attenuates neurodegeneration in mutant TDP-43 mice. , 2016, Human molecular genetics.

[43]  Catherina G. Becker,et al.  Systemic restoration of UBA1 ameliorates disease in spinal muscular atrophy , 2016, JCI insight.

[44]  T. Gillingwater.  Counting the cost of spinal muscular atrophy , 2016, Journal of medical economics.

[45]  Aaron R. Poole,et al.  SMN and coilin negatively regulate dyskerin association with telomerase RNA , 2016, Biology Open.

[46]  M. Walter,et al.  Disease burden of spinal muscular atrophy in Germany , 2016, Orphanet Journal of Rare Diseases.

[47]  W. Rossoll,et al.  Deficiency of the Survival of Motor Neuron Protein Impairs mRNA Localization and Local Translation in the Growth Cone of Motor Neurons , 2016, The Journal of Neuroscience.

[48]  Jacqueline Montes,et al.  Results from a phase 1 study of nusinersen (ISIS-SMNRx) in children with spinal muscular atrophy , 2016, Neurology.

[49]  Rachael A. Powis,et al.  Selective loss of alpha motor neurons with sparing of gamma motor neurons and spinal cord cholinergic neurons in a mouse model of spinal muscular atrophy , 2016, Journal of anatomy.

[50]  Chunyi Zhou,et al.  Defects in Motoneuron–Astrocyte Interactions in Spinal Muscular Atrophy , 2016, The Journal of Neuroscience.

[51]  F. Muntoni,et al.  Vascular Defects and Spinal Cord Hypoxia in Spinal Muscular Atrophy , 2016, Annals of neurology.

[52]  G. Dreyfuss,et al.  A U1 snRNP-Specific Assembly Pathway Reveals the SMN Complex as a Versatile RNP Exchange , 2016, Nature Structural &Molecular Biology.

[53]  A. Khandji,et al.  Intrathecal Injections in Children With Spinal Muscular Atrophy , 2016, Journal of child neurology.

[54]  B. Mandefro,et al.  Spinal Muscular Atrophy Patient iPSC-Derived Motor Neurons Have Reduced Expression of Proteins Important in Neuronal Development , 2016, Front. Cell. Neurosci..

[55]  Xiaoqing Zhang,et al.  Abnormal mitochondrial transport and morphology as early pathological changes in human models of spinal muscular atrophy , 2016, Disease Models & Mechanisms.

[56]  J. Côté,et al.  A novel role for CARM1 in promoting nonsense-mediated mRNA decay: potential implications for spinal muscular atrophy , 2015, Nucleic acids research.

[57]  D. Malone,et al.  The economic burden of spinal muscular atrophy , 2015, Journal of medical economics.

[58]  J. Côté,et al.  A novel role for CARM 1 in promoting nonsense-mediated mRNA decay : potential implications for spinal muscular atrophy , 2016 .

[59]  R. Finkel,et al.  Spinal muscular atrophy functional composite score: A functional measure in spinal muscular atrophy , 2015, Muscle & nerve.

[60]  J. Henne,et al.  Understanding the experiences and needs of individuals with Spinal Muscular Atrophy and their parents: a qualitative study , 2015, BMC Neurology.

[61]  Christine Y. Lu,et al.  Access to Orphan Drugs: A Comprehensive Review of Legislations, Regulations and Policies in 35 Countries , 2015, PloS one.

[62]  Ewout J. N. Groen,et al.  UBA1: At the Crossroads of Ubiquitin Homeostasis and Neurodegeneration , 2015, Trends in molecular medicine.

[63]  L. Pellizzoni,et al.  Disease Mechanisms and Therapeutic Approaches in Spinal Muscular Atrophy , 2015, The Journal of Neuroscience.

[64]  Michael A. Freitas,et al.  Spinal Muscular Atrophy Biomarker Measurements from Blood Samples in a Clinical Trial of Valproic Acid in Ambulatory Adults , 2015, Journal of neuromuscular diseases.

[65]  G. Comi,et al.  Impaired Muscle Mitochondrial Biogenesis and Myogenesis in Spinal Muscular Atrophy. , 2015, JAMA neurology.

[66]  J. Jasper,et al.  The Small-Molecule Fast Skeletal Troponin Activator, CK-2127107, Improves Exercise Tolerance in a Rat Model of Heart Failure , 2015, The Journal of Pharmacology and Experimental Therapeutics.

[67]  J. Carulli,et al.  Newborn blood spot screening test using multiplexed real-time PCR to simultaneously screen for spinal muscular atrophy and severe combined immunodeficiency. , 2015, Clinical chemistry.

[68]  Gene W. Yeo,et al.  ALS-causative mutations in FUS/TLS confer gain- and loss-of-function by altered association with SMN and U1-snRNP , 2015, Nature Communications.

[69]  B. Wirth,et al.  SMN regulates axonal local translation via miR-183/mTOR pathway. , 2014, Human molecular genetics.

[70]  Anirvan Ghosh,et al.  SMN2 splicing modifiers improve motor function and longevity in mice with spinal muscular atrophy , 2014, Science.

[71]  T. Gillingwater,et al.  SMN-dependent intrinsic defects in Schwann cells in mouse models of spinal muscular atrophy. , 2014, Human molecular genetics.

[72]  A. Joshi,et al.  Dysregulation of ubiquitin homeostasis and β-catenin signaling promote spinal muscular atrophy. , 2014, The Journal of clinical investigation.

[73]  T. Akay,et al.  Requirement of enhanced Survival Motoneuron protein imposed during neuromuscular junction maturation. , 2014, The Journal of clinical investigation.

[74]  C. Holt,et al.  The Central Dogma Decentralized: New Perspectives on RNA Function and Local Translation in Neurons , 2013, Neuron.

[75]  Ewout J. N. Groen,et al.  ALS-associated mutations in FUS disrupt the axonal distribution and function of SMN. , 2013, Human molecular genetics.

[76]  K. Fischbeck,et al.  The E3 ubiquitin ligase mind bomb 1 ubiquitinates and promotes the degradation of survival of motor neuron protein , 2013, Molecular biology of the cell.

[77]  T. Gillingwater,et al.  Mechanisms underlying synaptic vulnerability and degeneration in neurodegenerative disease , 2013, Neuropathology and applied neurobiology.

[78]  É. Khandjian,et al.  A novel function for the survival motoneuron protein as a translational regulator. , 2013, Human molecular genetics.

[79]  F. Muntoni,et al.  A novel morpholino oligomer targeting ISS-N1 improves rescue of severe spinal muscular atrophy transgenic mice. , 2013, Human gene therapy.

[80]  E. Tizzano,et al.  Synaptic defects in type I spinal muscular atrophy in human development , 2013, The Journal of pathology.

[81]  S. Lefebvre,et al.  Implication of the SMN complex in the biogenesis and steady state level of the Signal Recognition Particle , 2012, Nucleic acids research.

[82]  G. Hamilton,et al.  Spinal muscular atrophy: going beyond the motor neuron. , 2013, Trends in molecular medicine.

[83]  C. Lorson,et al.  SMN-inducing compounds for the treatment of spinal muscular atrophy. , 2012, Future medicinal chemistry.

[84]  L. H. van den Berg,et al.  Dysfunction of the neuromuscular junction in spinal muscular atrophy types 2 and 3 , 2012, Neurology.

[85]  Junmin Peng,et al.  Ubiquitin-specific Protease 9x Deubiquitinates and Stabilizes the Spinal Muscular Atrophy Protein-Survival Motor Neuron* , 2012, The Journal of Biological Chemistry.

[86]  S. Gygi,et al.  FUS-SMN protein interactions link the motor neuron diseases ALS and SMA. , 2012, Cell reports.

[87]  S. Dobrowolski,et al.  Newborn screening for spinal muscular atrophy by calibrated short-amplicon melt profiling. , 2012, Clinical chemistry.

[88]  R. Finkel,et al.  Evaluation of SMN Protein, Transcript, and Copy Number in the Biomarkers for Spinal Muscular Atrophy (BforSMA) Clinical Study , 2012, PloS one.

[89]  M. Bowerman,et al.  Fasudil improves survival and promotes skeletal muscle development in a mouse model of spinal muscular atrophy , 2012, BMC Medicine.

[90]  B. Wirth,et al.  The spinal muscular atrophy disease protein SMN is linked to the Rho-kinase pathway via profilin. , 2011, Human molecular genetics.

[91]  Adrian R. Krainer,et al.  Peripheral SMN restoration is essential for long-term rescue of a severe SMA mouse model , 2011, Nature.

[92]  A. MacKenzie,et al.  Prolactin increases SMN expression and survival in a mouse model of severe spinal muscular atrophy via the STAT5 pathway. , 2011, The Journal of clinical investigation.

[93]  M. Schroth,et al.  SMA CARNI-VAL TRIAL PART II: A Prospective, Single-Armed Trial of L-Carnitine and Valproic Acid in Ambulatory Children with Spinal Muscular Atrophy , 2011, PloS one.

[94]  J. Steen,et al.  Interaction of survival of motor neuron (SMN) and HuD proteins with mRNA cpg15 rescues motor neuron axonal deficits , 2011, Proceedings of the National Academy of Sciences.

[95]  R. Singer,et al.  The Survival of Motor Neuron (SMN) Protein Interacts with the mRNA-Binding Protein HuD and Regulates Localization of Poly(A) mRNA in Primary Motor Neuron Axons , 2011, The Journal of Neuroscience.

[96]  N. Chatauret,et al.  Intravenous scAAV9 delivery of a codon-optimized SMN1 sequence rescues SMA mice. , 2011, Human molecular genetics.

[97]  Michael J. O'Donovan,et al.  Early Functional Impairment of Sensory-Motor Connectivity in a Mouse Model of Spinal Muscular Atrophy , 2011, Neuron.

[98]  J. Côté,et al.  HuD interacts with survival motor neuron protein and can rescue spinal muscular atrophy-like neuronal defects. , 2011, Human molecular genetics.

[99]  A. Verma.  Rescue of the spinal muscular atrophy phenotype in a mouse model by early postnatal delivery of SMN , 2011 .

[100]  K. Foust,et al.  Early heart failure in the SMNDelta7 model of spinal muscular atrophy and correction by postnatal scAAV9-SMN delivery. , 2010, Human molecular genetics.

[101]  A. Grierson,et al.  Systemic Delivery of scAAV9 Expressing SMN Prolongs Survival in a Model of Spinal Muscular Atrophy , 2010, Science Translational Medicine.

[102]  M. Bowerman,et al.  Rho-kinase inactivation prolongs survival of an intermediate SMA mouse model. , 2010, Human molecular genetics.

[103]  B. Wirth,et al.  SAHA ameliorates the SMA phenotype in two mouse models for spinal muscular atrophy. , 2010, Human molecular genetics.

[104]  K. Klinger,et al.  CNS-targeted gene therapy improves survival and motor function in a mouse model of spinal muscular atrophy. , 2010, The Journal of clinical investigation.

[105]  K. Talbot,et al.  Pre-symptomatic development of lower motor neuron connectivity in a mouse model of severe spinal muscular atrophy. , 2010, Human molecular genetics.

[106]  Kay E. Davies,et al.  Alternative Splicing Events Are a Late Feature of Pathology in a Mouse Model of Spinal Muscular Atrophy , 2009, PLoS genetics.

[107]  M. Khaidakov,et al.  Mitochondrial dysfunction in a neural cell model of spinal muscular atrophy , 2009, Journal of neuroscience research.

[108]  M. Rich,et al.  Impaired Synaptic Vesicle Release and Immaturity of Neuromuscular Junctions in Spinal Muscular Atrophy Mice , 2009, The Journal of Neuroscience.

[109]  L. Landmesser,et al.  Reduced SMN protein impairs maturation of the neuromuscular junctions in mouse models of spinal muscular atrophy. , 2008, Human molecular genetics.

[110]  Mitchell R Lunn,et al.  Spinal muscular atrophy , 2008, The Lancet.

[111]  Lili Wan,et al.  SMN Deficiency Causes Tissue-Specific Perturbations in the Repertoire of snRNAs and Widespread Defects in Splicing , 2008, Cell.

[112]  B. Wirth,et al.  Plastin 3 Is a Protective Modifier of Autosomal Recessive Spinal Muscular Atrophy , 2008, Science.

[113]  K. Talbot,et al.  Selective vulnerability of motor neurons and dissociation of pre- and post-synaptic pathology at the neuromuscular junction in mouse models of spinal muscular atrophy. , 2008, Human molecular genetics.

[114]  E. Hoffman,et al.  Rare missense and synonymous variants in UBE1 are associated with X-linked infantile spinal muscular atrophy. , 2008, American journal of human genetics.

[115]  M. Bowerman,et al.  Smn Depletion Alters Profilin II Expression and Leads to Upregulation of the RhoA/ROCK Pathway and Defects in Neuronal Integrity , 2007, Journal of Molecular Neuroscience.

[116]  K. Fischbeck,et al.  Trichostatin A increases SMN expression and survival in a mouse model of spinal muscular atrophy. , 2007, The Journal of clinical investigation.

[117]  Martin J. Pollard,et al.  The complete sequence of human chromosome 5 , 2004 .

[118]  Paul Richardson,et al.  The DNA sequence and comparative analysis of human chromosome 5 , 2004, Nature.

[119]  Michael Sendtner,et al.  Smn, the spinal muscular atrophy–determining gene product, modulates axon growth and localization of β-actin mRNA in growth cones of motoneurons , 2003, The Journal of cell biology.

[120]  H. Budka,et al.  Severe depletion of mitochondrial DNA in spinal muscular atrophy , 2003, Acta Neuropathologica.

[121]  J. Yong,et al.  Essential Role for the SMN Complex in the Specificity of snRNP Assembly , 2002, Science.

[122]  J. Melki,et al.  Neurofilament accumulation at the motor endplate and lack of axonal sprouting in a spinal muscular atrophy mouse model. , 2002, Human molecular genetics.

[123]  D R Bentley,et al.  The DNA sequence and comparative analysis of human chromosome 20 , 2004, Nature.

[124]  G. Dreyfuss,et al.  The survival of motor neurons (SMN) protein interacts with the snoRNP proteins fibrillarin and GAR1 , 2001, Current Biology.

[125]  U. Monani,et al.  The human centromeric survival motor neuron gene (SMN2) rescues embryonic lethality in Smn(-/-) mice and results in a mouse with spinal muscular atrophy. , 2000, Human molecular genetics.

[126]  J. McPherson,et al.  A single nucleotide difference that alters splicing patterns distinguishes the SMA gene SMN1 from the copy gene SMN2. , 1999, Human molecular genetics.

[127]  C. Lorson,et al.  A single nucleotide in the SMN gene regulates splicing and is responsible for spinal muscular atrophy. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[128]  A. Munnich,et al.  The distribution of SMN protein complex in human fetal tissues and its alteration in spinal muscular atrophy. , 1998, Human molecular genetics.

[129]  M. Zeviani,et al.  Expression of the SMN gene, the spinal muscular atrophy determining gene, in the mammalian central nervous system. , 1997, Human molecular genetics.

[130]  G. Dreyfuss,et al.  The Spinal Muscular Atrophy Disease Gene Product, SMN, and Its Associated Protein SIP1 Are in a Complex with Spliceosomal snRNP Proteins , 1997, Cell.

[131]  G. Dreyfuss,et al.  The SMN–SIP1 Complex Has an Essential Role in Spliceosomal snRNP Biogenesis , 1997, Cell.

[132]  T. Crawford,et al.  The survival motor neuron protein in spinal muscular atrophy. , 1997, Human molecular genetics.

[133]  Arnold Munnich,et al.  Correlation between severity and SMN protein level in spinal muscular atrophy , 1997, Nature Genetics.

[134]  J. Weissenbach,et al.  Identification and characterization of a spinal muscular atrophy-determining gene , 1995, Cell.